Abstract: The present invention relates to chromans, to processes for their preparation and to their use in medicaments, in particular as agents for treating disorders of the central nervous system.

Abstract: The invention relates to the use of an adsorption material which has been modified with polynuclear metal oxide hydroxides for influencing the calcium level and, in particular, for treating or/and preventing atherosclerotic vascular diseases or/and disturbances of bone metabolism.

Abstract: The present invention relates to a process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane with the aid of continuous countercurrent chromatography, which is also described as SMB chromatography (SMB=simulated moving bed).

Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: The invention relates to the crystalline form of the hydrochloride of the compound (R)-(-)-2-{N-?4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl! -aminomethyl}-chroman, which is present as a stable form at room temperature. The crystalline modification V of the hydrochloride is suitable in particular for the preparation of solid medicaments, in particular of medicaments for the treatment of neuronal degenerations.

Abstract: A process and a reagent for the specific and direct determination of the LDL-fraction in the presence of other serum lipoproteins by adding a polymeric LDL-aggregating agent, followed by direct turbidimetric measurement of the LDL aggregate. Preferred are polymers which have a comb or brush type structure with the side groups having acid character, such as branched alkane sulfonic acids.

Abstract: Disclosed is a process to remove tumour necrosis factor .alpha. (TNF.alpha.) or/and bacterial lipopolysaccharides (LPS) from an aqueous liquid, in particular blood, blood plasma or serum, in an extracorporeal perfusion system after removing corpuscular blood components if necessary, wherein(a) the pH value of the body fluid is adjusted to pH<6,(b) a precipitation reagent in the form of a polyanion is added,(c) precipitated substances are removed by filtration or/and centrifugation and(d) the resulting liquid is passed over an anion exchanger.

Abstract: In order to remove tumor necrosis factor .alpha. (TNF.alpha.) or/and bacterial lipopolysaccharides (LPS, endotoxin) extracorporeally from whole blood or/and blood plasma in an extracorporeal perfusion system, the blood or plasma is passed over a cation exchanger and an anion exchanger material. A device according to the invention for the extracorporeal treatment of patient's blood or plasma therefore contains a cation exchanger material and an anion exchanger material wherein these materials are contained in at least one compartment of an extracorporeal perfusion system.

Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: A process for the specific adsorption of heparin and other heparin-like substances which comprises flowing a buffered solution of whole blood, from which corpuscular blood constituents have been removed, plasma and/or solutions containing whole blood or plasma through an adsorber capsule containing a medium that adsorbs heparin and other heparin-like substances at an acid pH, preferably in the range of 4.0 to 5.5. Preferably, the process is carried out in a closed, extracorporeal circulation and the medium possesses anion exchange resin properties.

Abstract: Processes are described for the selective extracorporeal precipitation of low density lipoproteins or beta-lipoproteins from whole serum or plasma, wherein a treating agent comprising heparin or a polyanion, such as dextran sulfate or sodium-phosphorus tungstate, in a buffer is added to the whole serum or plasma and the beta-llipoprotein-complex which thereupon forms with the treating agent is precipitated at the isoelectric point at a pH value in the range of from about 5.05 to about 5.25, and is then separated. Optionally, the precipitate or respecively the filtrate is further analyzed for diagnostic purposes. When heparin is employed, the process may be employed therapeutically.Apparatus is described for the continuous therapeutic practice of such a process, employing heparin, including means for flushing to reduce clogging of the filter employed to separate the precipitated lipoprotein-complex.

Abstract: A method of precipitating low-density lipoproteins which comprises administering to a volume of blood, plasma or solutions containing blood or plasma a therapeutically or diagnostically effective amount of a low-density lipoprotein precipitating substance at an acid pH such that an anticoagulent effect associated with heparin is minimized or eliminated. The substances utilized in such a method include hydrolyzed heparin, hydrolyzed heparin acylated at free amine groups, sulfated glycosamino glycan and sulfated polysaccharides.

Abstract: A process and device for the selective separation of pathological and/or toxic species from blood, plasma or serum wherein a plasma or serum fraction is passed through a container containing one or more filter candles of decreasing means pore diameter and which may contain a sterilizable spacing disc between the filter candles. In accordance with the invention, macromolecular pathological and/or toxic species with molecular weight exclusion limits between about 20,000 and 3,000,000 D may be selectively separated from a fraction of plasma or serum.

Abstract: The invention relates to processes and apparatus employing filter candles with an effective filter surface area of 0.2 to 2 square meters and a mean pore diameter of 0.2 to 2 micron in sterilizable cylindrical housings for the selective extracorporeal separation of precipitates of macromolecular pathologic and/or toxic species from blood or blood constituents, such as whole serum or plasma.

Abstract: A method of preserving the electrophoretic properties of lipoproteins in human or animal plasma, plasma fractions or sera, in which the lipoprotein pattern is to be electrophoretically determined, consists in that non-reducing sugars are added to the plasma, plasma fractions or sera, the mixture is lyophilized and the lyophilizate is reconstituted prior to determination.